Assessment of a noninvasive exhaled breath test for the diagnosis of oesophagogastric cancer
File(s)jamaoncology_Markar_2018_oi_180023.pdf (220.86 KB)
Published version
Author(s)
Type
Journal Article
Abstract
Importance Early esophagogastric cancer (OGC) stage presents with nonspecific symptoms.
Objective The aim of this study was to determine the accuracy of a breath test for the diagnosis of OGC in a multicenter validation study.
Design, Setting, and Participants Patient recruitment for this diagnostic validation study was conducted at 3 London hospital sites, with breath samples returned to a central laboratory for selected ion flow tube mass spectrometry (SIFT-MS) analysis. Based on a 1:1 cancer:control ratio, and maintaining a sensitivity and specificity of 80%, the sample size required was 325 patients. All patients with cancer were on a curative treatment pathway, and patients were recruited consecutively. Among the 335 patients included; 172 were in the control group and 163 had OGC.
Interventions Breath samples were collected using secure 500-mL steel breath bags and analyzed by SIFT-MS. Quality assurance measures included sampling room air, training all researchers in breath sampling, regular instrument calibration, and unambiguous volatile organic compounds (VOCs) identification by gas chromatography mass spectrometry.
Main Outcomes and Measures The risk of cancer was identified based on a previously generated 5-VOCs model and compared with histopathology-proven diagnosis.
Results Patients in the OGC group were older (median [IQR] age 68 [60-75] vs 55 [41-69] years) and had a greater proportion of men (134 [82.2%]) vs women (81 [47.4%]) compared with the control group. Of the 163 patients with OGC, 123 (69%) had tumor stage T3/4, and 106 (65%) had nodal metastasis on clinical staging. The predictive probabilities generated by this 5-VOCs diagnostic model were used to generate a receiver operator characteristic curve, with good diagnostic accuracy, area under the curve of 0.85. This translated to a sensitivity of 80% and specificity of 81% for the diagnosis of OGC.
Conclusions and Relevance This study shows the potential of breath analysis in noninvasive diagnosis of OGC in the clinical setting. The next step is to establish the diagnostic accuracy of the test among the intended population in primary care where the test will be applied.
Introduction
Objective The aim of this study was to determine the accuracy of a breath test for the diagnosis of OGC in a multicenter validation study.
Design, Setting, and Participants Patient recruitment for this diagnostic validation study was conducted at 3 London hospital sites, with breath samples returned to a central laboratory for selected ion flow tube mass spectrometry (SIFT-MS) analysis. Based on a 1:1 cancer:control ratio, and maintaining a sensitivity and specificity of 80%, the sample size required was 325 patients. All patients with cancer were on a curative treatment pathway, and patients were recruited consecutively. Among the 335 patients included; 172 were in the control group and 163 had OGC.
Interventions Breath samples were collected using secure 500-mL steel breath bags and analyzed by SIFT-MS. Quality assurance measures included sampling room air, training all researchers in breath sampling, regular instrument calibration, and unambiguous volatile organic compounds (VOCs) identification by gas chromatography mass spectrometry.
Main Outcomes and Measures The risk of cancer was identified based on a previously generated 5-VOCs model and compared with histopathology-proven diagnosis.
Results Patients in the OGC group were older (median [IQR] age 68 [60-75] vs 55 [41-69] years) and had a greater proportion of men (134 [82.2%]) vs women (81 [47.4%]) compared with the control group. Of the 163 patients with OGC, 123 (69%) had tumor stage T3/4, and 106 (65%) had nodal metastasis on clinical staging. The predictive probabilities generated by this 5-VOCs diagnostic model were used to generate a receiver operator characteristic curve, with good diagnostic accuracy, area under the curve of 0.85. This translated to a sensitivity of 80% and specificity of 81% for the diagnosis of OGC.
Conclusions and Relevance This study shows the potential of breath analysis in noninvasive diagnosis of OGC in the clinical setting. The next step is to establish the diagnostic accuracy of the test among the intended population in primary care where the test will be applied.
Introduction
Date Issued
2018-07-01
Date Acceptance
2018-02-16
Citation
JAMA Oncology, 2018, 4 (7), pp.970-976
ISSN
2374-2445
Publisher
American Medical Association
Start Page
970
End Page
976
Journal / Book Title
JAMA Oncology
Volume
4
Issue
7
Copyright Statement
This is an open access article distributed under the terms of the CC-BY License. © 2018 Markar SR et al. JAMA Oncology. (https://jamanetwork.com/journals/jamaoncology/pages/instructions-for-authors#SecOpenAccess)
Sponsor
Biotechnology and Biological Sciences Research Council (BBSRC)
Biotechnology and Biological Sciences Research Cou
Engineering & Physical Science Research Council (EPSRC)
European Research Council
Imperial Health Charity
National Institute for Health Research
National Institute for Health Research
Grant Number
BB/L018268/1
4020012831
EP/N002474/1
319818
141514
DRF-2014-07-088
NIHR-CTF-2015-04-09
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
VOLATILE ORGANIC-COMPOUNDS
TUBE MASS-SPECTROMETRY
FECAL OCCULT BLOOD
ESOPHAGEAL CANCER
SIFT-MS
METABOLITES
BIOMARKERS
ONLINE
URINE
LUNG
Adult
Aged
Breath Tests
Esophageal Neoplasms
Female
Humans
Male
Middle Aged
Stomach Neoplasms
Humans
Esophageal Neoplasms
Stomach Neoplasms
Breath Tests
Adult
Aged
Middle Aged
Female
Male
1112 Oncology and Carcinogenesis
1117 Public Health and Health Services
Publication Status
Published
Date Publish Online
2018-05-17